<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <title>Reporting Amount of Listed Drugs and Biological Products Under Section 510(j)(3) of the Federal Food, Drug, and Cosmetic Act; Draft Guidance for Industry; Availability</title>
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <style>
        body { font-family: Arial, sans-serif; max-width: 800px; margin: 0 auto; padding: 20px; }
        h1 { color: #333; }
        .metadata { color: #666; font-size: 0.9em; }
        .summary { margin-top: 20px; line-height: 1.5; }
        .source { margin-top: 20px; }
    </style>
</head>
<body>
    <h1>Reporting Amount of Listed Drugs and Biological Products Under Section 510(j)(3) of the Federal Food, Drug, and Cosmetic Act; Draft Guidance for Industry; Availability</h1>
    <div class="metadata">Published: 2026-02-05 12:26:41</div>
    <div class="summary">The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled "Reporting Amount of Listed Drugs and Biological Products Under Section 510(j)(3) of the FD&C Act." This draft guidance addresses the process through which registrants of drug establishments should submit to FDA reports on the amount of each listed drug manufactured, prepared, propagated, compounded, or processed for commercial distribution, as required by the Federal Food, Drug, and Cosmetic Act (FD&C Act).</div>
    <div class="source">Source: <a href="https://www.federalregister.gov/documents/2021/11/01/2021-23722/reporting-amount-of-listed-drugs-and-biological-products-under-section-510j3-of-the-federal-food" target="_blank" rel="noopener noreferrer">https://www.federalregister.gov/documents/2021/11/01/2021-23722/reporting-amount-of-listed-drugs-and-biological-products-under-section-510j3-of-the-federal-food</a></div>
</body>
</html>
